close

Fundraisings and IPOs

Date: 2019-04-08

Type of information: Private placement

Company: Sangamo Therapeutics (USA-CA)

Investors:

Amount: $136.3 million

Funding type: public offering

Planned used: Sangamo anticipates using the net proceeds from the offering for working capital and other general corporate purposes, including support for its own and its partnered gene therapy, genome editing, cell therapy and gene regulation product candidates and research programs, its manufacturing facilities and other business development activities. In April 2019, we completed an underwritten public offering of our common stock, in which we sold an aggregate of 12.7 million shares of our common stock at a public offering price of $11.50 per share.

Others:

  • • On April 8, 2019, Sangamo Therapeutics announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Sangamo. Including the option exercise, the aggregate gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $145.5 million. The net proceeds from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, are approximately $136.3 million. Cowen and Company, LLC, Wells Fargo Securities, LLC and Barclays Capital Inc. acted as joint book-running managers for the offering.
  • • On April 4, 2019, Sangamo Therapeutics announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share. The gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $126.5 million. The offering is expected to close on or about April 8, 2019, subject to customary closing conditions. In addition, Sangamo has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
  • • On April 3, 2019, Sangamo Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Sangamo.

Therapeutic area:

Is general: Yes